5-(3-溴苯基)-1-甲基-1H-咪唑 | 1218910-50-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-(3-溴苯基)-1-甲基-1H-咪唑
• 中文别名: 5-(3-溴苯基)-1-甲基咪唑
• 英文名称: 5-(3-Bromophenyl)-1-methylimidazole
• 英文别名: 5-(3-bromophenyl)-1-methylimidazole
• CAS: 1218910-50-9
• 化学式: C₁₀H₉BrN₂
• 分子量: 237.099
• InChiKey: ZBKTVJWYHULGAW-UHFFFAOYSA-N

物化性质

• 沸点：
  387.0±17.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-(3-溴苯基)-1-甲基-1H-咪唑 、 2,6-二甲基苯硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 5-[3-(2,6-Dimethylphenyl)phenyl]-1-methylimidazole
  参考文献：
  名称：

  Discovery of biaryl inhibitors of H+/K+ ATPase

  摘要：

  We report the identification of a novel biaryl template for H+/K+ ATPase inhibition. Evaluation of critical SAR features within the biaryl imidazole framework and the use of pharmacophore modelling against known imidazopyridine and azaindole templates suggested that the geometry of the molecule is key to achieving activity. Herein we present our work optimising the potency of the molecule through modi. cations and substitutions to each of the ring systems. In particular sub-micromolar potency is achieved with (4b) presumably through a proposed intramolecular hydrogen bond that ensures the required imidazole basic centre is appropriately located. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.040
• 作为产物：
  描述：

  5-溴-1-甲基-1H-咪唑 、 3-溴苯硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 5-(3-溴苯基)-1-甲基-1H-咪唑
  参考文献：
  名称：

  Discovery of biaryl inhibitors of H+/K+ ATPase

  摘要：

  We report the identification of a novel biaryl template for H+/K+ ATPase inhibition. Evaluation of critical SAR features within the biaryl imidazole framework and the use of pharmacophore modelling against known imidazopyridine and azaindole templates suggested that the geometry of the molecule is key to achieving activity. Herein we present our work optimising the potency of the molecule through modi. cations and substitutions to each of the ring systems. In particular sub-micromolar potency is achieved with (4b) presumably through a proposed intramolecular hydrogen bond that ensures the required imidazole basic centre is appropriately located. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.040

文献信息

• Libraries of C-5 Substituted Imidazoles and Oxazoles by Sequential Van Leusen (VL)-Suzuki, VL-Heck and VL-Sonogashira in Imidazolium-ILs with Piperidine-Appended-IL as Base
  作者：Hemantkumar M. Savanur、Rajesh G. Kalkhambkar、Kenneth K. Laali

  DOI：10.1002/ejoc.201800804

  日期：2018.10.17

  By sequencing the Van Leusen imidazole and oxazole syntheses with Suzuki, Heck and Sonogashira reactions, diverse libraries of C5‐functionalized imidazoles and oxazoles were synthesized in one‐pot reactions employing [BMIM][X] as a solvent and [PAIM][NTf2] as a base.

  通过使用Suzuki，Heck和Sonogashira反应对Van Leusen咪唑和恶唑合成物进行测序，使用[BMIM] [X]作为溶剂和[PAIM] [NTf 2 ]为基础。
• FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST
  申请人：RaQualia Pharma Inc.

  公开号：EP3774739B1

  公开（公告）日：2022-05-11